Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?
Lorbrena, Non-small cell lung cancer, Oncology, Pfizer, Xalkori
0 Comment
Xalkori
Takeda sets sights on first-line lung cancer market with new Alunbrig data
Alecensa, Alunbrig, Non-small cell lung cancer, Novartis, Oncology, Pfizer, Roche, Takeda, Xalkori
0 Comment
NICE recommends Pfizer’s Xalkori in rare lung cancer
lung cancer, NSCLC, Pfizer, rare cancer, rare disease, Xalkori
0 Comment
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
